Large companies in the health care space, such as drugmaker Merck (NYSE: MRK ) , are typically insulated from general secular trends and tend to make good defensive plays for long-term investors. However, this rule of thumb should be taken with a grain of salt; not every pharmaceutical company is the right fit for your portfolio, and investors always need to consider the bull and bear theses of their investments. In this video, our health care analyst dives into the bear thesis for Merck.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. or more detailed information, make sure you take a look at our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.